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Abstract  27 
The human papillomavirus (HPV) replication cycle is tightly linked to epithelial cell 28 
differentiation. To examine HPV-associated changes in the keratinocyte transcriptome, 29 
RNAs isolated from undifferentiated and differentiated cell populations of normal, 30 
spontaneously immortalised, keratinocytes (NIKS), and NIKS stably transfected with HPV16 31 
episomal genomes (NIKS16), were compared using RNASeq. HPV16 infection altered 32 
expression of 2862 cellular genes. Next, to elucidate the role of keratinocyte gene 33 
expression in late events during the viral life cycle, RNASeq was carried out on triplicate 34 
differentiated populations of NIKS (uninfected) and NIKS16 (infected). Of the top 966 genes 35 
altered (>log2 = 1.8, 3.5-fold change) 670 genes were downregulated and 296 genes were 36 
up-regulated. HPV down-regulated many genes involved in epithelial barrier function that 37 
involves structural resistance to the environment and immunity to infectious agents. For 38 
example, HPV infection repressed expression of the differentiated keratinocyte-specific 39 
pattern recognition receptor TLR7, the Langerhans cell chemoattractant, CCL20, and 40 
proinflammatory cytokines, IL1A and IL1B. However, IRF1, IFNκ and viral restriction factors 41 
(IFIT1, 2, 3, 5, OASL, CD74, RTP4) were up-regulated. HPV infection abrogated gene 42 
expression associated with the physical epithelial barrier, including keratinocyte 43 
cytoskeleton, intercellular junctions and cell adhesion. qPCR and western blotting confirmed 44 
changes in expression of seven of the most significantly altered mRNAs. Expression of three 45 
genes showed statistically significant changes during cervical disease progression in clinical 46 
samples. Taken together, the data indicate that HPV infection manipulates the differentiating 47 
keratinocyte transcriptome to create an environment conducive to productive viral replication 48 
and egress.  49 
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Importance 51 
Human papillomavirus (HPV) genome amplification and capsid formation takes place in 52 
differentiated keratinocytes. The viral life cycle is intimately associated with host cell 53 
differentiation. Deep sequencing (RNASeq) of RNA from undifferentiated and differentiated 54 
uninfected and HPV16-positive keratinocytes showed that almost 3000 genes were 55 
differentially expressed in keratinocyte due to HPV16 infection. Strikingly, the epithelial 56 
barrier function of differentiated keratinocytes, comprising keratinocyte immune function and 57 
cellular structure, was found to be disrupted. These data provide new insights into virus-host 58 
interaction crucial for production of infectious virus and reveal that HPV infection remodels 59 
keratinocytes for completion of the virus replication cycle. 60 
 61 
 62 
 63 
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Introduction 68 
Human papillomaviruses (HPVs) infect keratinocytes, causing mainly benign lesions or warts 69 
(1). Infection is usually transient and is cleared by the immune system (2). However, 70 
persistent infection with “high risk” HPV genotypes (HR-HPV) can cause tumour progression 71 
to cervical (3), other anogenital (anal, penile, vulvar and vaginal) (4) and oropharyngeal 72 
cancers (5). In the case of the cervix, cervical intraepithelial neoplasia (CIN) generally 73 
precedes cervical cancer progression (6). CIN1 is thought to represent a transient HPV 74 
infection, while CIN3 represents clinically significant, persistent HPV infection that may, if left 75 
untreated, progress to cervical cancer (7).  76 
The pathway of epithelial cell differentiation, from basal to granular layer, is tightly controlled 77 
by complex patterns of keratinocyte gene expression (8). The HPV infectious life cycle is 78 
tightly linked to epithelial differentiation. HPV infects basal epithelial cells where it begins to 79 
express its genome. The viral replication factor E1 and its auxiliary protein, E2, which is also 80 
the viral transcription factor, together with the regulatory proteins E6 and E7 are expressed 81 
early in infection. E2, E6 and E7 have each been shown to control cellular gene expression 82 
(6). Viral gene expression required for vegetative viral genome amplification takes place in 83 
differentiating keratinocytes in the mid to upper epithelial layers (9). At this stage other viral 84 
regulatory proteins E4 and E5 that can regulate the host cell are expressed (6). Finally, L1 85 
and L2 capsid protein synthesis and virion formation takes place in granular layer 86 
keratinocytes and virions are shed from the surface of the epithelium in dead squames (10). 87 
The epithelium presents a barrier to the environment and to infectious agents (11). 88 
Differentiated keratinocytes possess a dense filamentous network comprised of keratins and 89 
other molecules such as filaggrin. Moreover, keratinocytes have an important role in innate 90 
and adaptive immunity, and cytokines, chemokines and other immune signalling molecules 91 
released by these cells are essential for epithelial homeostasis (12). HPVs have evolved to 92 
modulate the epithelium to allow infection, virion formation and egress (6), and many means 93 
by which HPV evades the immune response have been documented (13). Elucidating the 94 
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interactions between HPV and the infected keratinocyte is key to understanding the HPV life 95 
cycle and how persistent infection may facilitate development of cervical disease. 96 
A number of previous studies have used a microarray approach to further our understanding 97 
of the HPV infectious life cycle and cancer progression. The first compared gene expression 98 
in normal keratinocytes with that in  HPV31-infected keratinocytes (14). Two subsequent 99 
studies examined gene expression changes during tumour progression in HPV18-infected 100 
(15)  or HPV33-infected keratinocytes (16). A recent study investigated undifferentiated 101 
keratinocytes containing HPV16 or HPV18 episomal genomes. However, no studies have 102 
analysed how cellular gene expression is altered in differentiating keratinocytes supporting 103 
the productive phase of the viral life cycle (17). Here we used Next Generation Sequencing 104 
(RNASeq) to examine global changes in the keratinocyte transcriptome due to epithelial 105 
differentiation and HPV infection. Our study reveals that HPV infection induces massive 106 
changes in the transcriptome during keratinocyte differentiation. In particular, changes in 107 
many genes encoding the keratinocyte structural barrier and immune function were altered. 108 
Key statistically highly significant changes in gene expression were confirmed by RT-qPCR 109 
and western blotting and investigated in clinical samples representing the cervical disease 110 
spectrum. These data can be used to understand late events in the viral life cycle and the 111 
mechanisms behind cervical disease progression. 112 
 113 
 114 
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Results 116 
The HPV E2 transcription factor (18) and the viral oncoproteins E6 (19), E7 (20) and E5 (21) 117 
can all play a role in controlling cellular gene expression, and HPV infection is known to have 118 
a significant effect on keratinocyte growth and differentiation (6). In order to elucidate how 119 
cellular gene expression is altered during HPV infection we examined changes in the 120 
keratinocyte transcriptome during differentiation and HPV16 infection using normal, 121 
spontaneously immortalised keratinocytes (NIKS) and the same cells stably transfected with 122 
HPV16 genomes (NIKS16). NIKS16 clone 2L maintains ~100 episomal HPV16 genomes per 123 
cell (if cultured at low passage (<13)) and forms a CIN1-like (low grade cervical disease) 124 
stratified epithelium upon raft culture, suggesting that these cells represent a transient 125 
HPV16 infection (22). We also examined a second HPV16 infection model, W12 cells, which 126 
are HPV16-infected basal cervical epithelial cells isolated from a patient with a low grade 127 
cervical lesion (23). W12 clone 20863 (W12E) cells (if cultured at low passage (<17)) also 128 
maintain ~100 episomal HPV16 genomes (24). Both cell lines are capable of differentiation. 129 
We used the differentiation protocol from Jeon et al (1995) where cells are induced to 130 
differentiation by culturing to high density in 1.2 mM Ca++.  Differentiated NIKS16 and W12E 131 
cell populations expressed involucrin, loricrin and keratin 10 proteins, key markers of 132 
keratinocyte differentiation, (Figure 1A). NIKS16 cells (and W12 cells (25)) expressed viral 133 
late proteins E2, E4 and L1 (Figure 1A, B). A time course of NIKS and NIKS16 differentiation 134 
over a 13 day period is shown in Figure 1C. As expected, NIKS cells (Figure 1C lanes 1-4) 135 
expressed more involucrin over the time course than NIKS16 cells (Figure 1C lanes 5-8) 136 
because HPV infection impairs epithelial differentiation (6). Absolute quantification of viral 137 
genome copies by PCR showed that differentiated W12 cells had an average of 15,250 138 
genome copies while there was an average of 9937 copies NIKS16 cells (Figure 1D). Viral 139 
late mRNA levels, as measured by L1 open reading frame detection, the common reading 140 
frame in all late mRNAs, was increased 16.1-fold in W12 cells and 12.6-fold in NIKS16 cells 141 
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upon differentiation (Figure 1E). These data indicate that NIKS16 and W12 cells can be 142 
differentiated in monolayer culture. 143 
Global changes in the transcriptome of HPV16-infected keratinocytes. 144 
RNASeq was carried out using RNA prepared from undifferentiated and differentiated NIKS 145 
and NIKS16 populations. Comparing undifferentiated with differentiated uninfected NIKS, 146 
809 mRNAs were up-regulated while 422 mRNAs were down-regulated (Figure 2A). In 147 
contrast, comparing undifferentiated to differentiated HPV16-infected NIKS16 keratinocytes, 148 
2041 genes were up-regulated while 2052 genes were down-regulated (Figure 2B). Because 149 
NIKS16 cells are derived directly from NIKS (22) and were differentiated using the same 150 
protocol, the 2862 additional changes observed upon differentiation of HPV16-positive 151 
keratinocytes are likely attributable to HPV infection. A similar number of gene expression 152 
changes to that for NIKS16 cells were observed between undifferentiated and differentiated 153 
W12E cells (data not shown). There is no HPV-negative equivalent to W12 cells but we 154 
compared the overlap of RNASeq changes in the transcriptome of differentiated W12 cells 155 
compared to NIKS cells and NIKS16 cells compared to the parent NIKS cells. Despite the 156 
fact that these cells are of different origin, W12 is a female HPV-immortalised mucosal 157 
epithelial cell line while NIKS is a spontaneously male cutaneous epithelial cell line, there 158 
was a 41% overlap in upregulated genes (Figure 2C) and a 38% overlap in downregulated 159 
genes (Figure 2D). These data suggest that the effects of HPV infection and the 160 
differentiation process is somewhat similar both cell types.   161 
 162 
HPV16 infection abrogates differentiation and epithelial barrier formation 163 
We are interested in elucidating the link between keratinocyte differentiation and late events 164 
during HPV replication. Therefore, we compared the transcriptome of differentiated NIKS to 165 
NIKS16 cells. Three, replicate, single-end sequencing experiments were carried out and 166 
changes that gave a p-value>0.05 across three replicates were discarded to achieve 167 
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significance. Supplementary Table S1 lists the top 966 changes in gene expression ( 168 
p<0.05, log2>1.8, 3.5-fold change). 670 genes were downregulated while 296 were 169 
upregulated, with a range of 184-fold downregulation to 87-fold up-regulated. The data in 170 
Figure 3 shows the mean of the results of three separate RNASeq experiments. As 171 
expected, key epithelial differentiation markers were down-regulated in NIKS16 cells (Figure 172 
3A). Suprabasal layer keratins were also down-regulated. Keratin 12, which is usually only 173 
expressed in the corneal epithelium (26), was the only keratin whose levels were increased 174 
in NIKS16 cells (Figure 3B). Expression of cell junction proteins that are key to epithelial 175 
barrier function was significantly altered. Desmosome cell-cell junction proteins required for 176 
cell adhesion (Figure 3C) (27), and gap junction connexin (Cx) proteins 26, 30 and 32, that 177 
allow transfer of small molecules between differentiating epithelial cells (28), were down-178 
regulated (Figure 3D). Claudin proteins control tight junctions, and CLDN3, 10 and 22 were 179 
up-regulated while CLDN11 and 17 were down-regulated (Figure 3E). Claudin upregulation 180 
can still have a negative impact on the function of tight junctions in a phenomenon referred 181 
to as “leaky claudins” (29). Several adherens junction-associated cadherins (27) were also 182 
down-regulated (Figure 3F). Small proline-rich repeat protein (SPRR) family members that 183 
contribute to barrier formation by forming the cornified layer in differentiated epithelial cells 184 
(30) were down-regulated (Figure 3G). The calcium gradient in the epithelium is altered upon 185 
loss of barrier formation (31) and levels of RNAs encoding a range of calcium ion-binding 186 
proteins (e.g. S100A8/A9 calgranulin complex, DSG1, matrix Gla protein (MGP), 187 
calcium/calmodulin kinase 2B (CAMK2B)) were reduced (Supplementary Table S3). Taken 188 
together, the data suggest that HPV infection inhibits epithelial barrier formation and 189 
epithelial integrity. 190 
The epithelial barrier also involves immune signalling and significant changes in expression 191 
of many genes whose products are involved in intrinsic and innate immunity were also 192 
observed (Table 1). Previously, a microarray study revealed that HR-HPV repressed 193 
activation of the immune response in undifferentiated epithelial cells through IL-1β. Similarly, 194 
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in HPV-infected differentiated cells we found IL1B gene expression was down-regulated. 195 
IL1A was also down-regulated, as were IL32G and IL36B that activate keratinocyte immune 196 
functions. The Langerhans cell chemoattractant CCL20 was down-regulated in the presence 197 
of HPV16. However, CCL28 that controls T-cell homing in mucosal epithelia, E6/E7-198 
regulated CXCL12 and CX3CL1 were all up-regulated. The type 1 IFN regulator, IRF1 and 199 
the epithelial IFNκ were up-regulated, an unexpected finding since HPVE6 and E7 have 200 
been shown to inhibit their expression (32-34). We found a 6-fold down-regulation of the viral 201 
DNA pattern recognition receptor TLR7, which is expressed specifically in differentiated 202 
keratinocytes (35), together with up-regulation of viral restriction factors APOBEC3B, IFIT1, 203 
2, 3 and 5, CD74, OASL and RTP4 (Table 1). These data indicate that the keratinocyte-204 
mediated immune response is under controlled of HPV16 in the upper epithelial layers, and 205 
that there are significant differences to HPV-regulation of immune signalling in differentiated, 206 
compared to basal, epithelial cells (17) 207 
 208 
Cellular networks involved in the immune response and keratinocyte structure and 209 
metabolism are altered by HPV16 infection. 210 
Following adjustment of the data set to exclude any changes where the triplicate values 211 
gave a p-value of >0.05, gene ontology network pathway analysis of the top 1000 up or 212 
down-regulated genes was carried out.  Analysis revealed distinct gene classes whose 213 
expression was altered by HPV16-infection (Figure 4). Response to type 1 interferon was 214 
up-regulated but cytokine and chemokine expression was repressed. Cell matrix adhesion 215 
was up-regulated while cell-cell adhesion was down-regulated (reported by the Cytoscape 216 
programme as negative regulation of up-regulated leukocyte genes) (Figure 4A). Other 217 
significantly down-regulated pathways included keratinization, arachidonic acid metabolism, 218 
reactive oxygen and nitric oxide biosynthesis, VEGF and temperature homeostasis (Figure 219 
4B). Network analysis indicated that pathways related to the type 1 interferon response were 220 
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strongly connected (Figure 4C) while down-regulated genes were associated through 221 
cytokine/chemokine/VEGF pathways (Figure 4D). A value of log2 change>2.5 was chosen to 222 
construct a wider pathway linkage diagram.  IRF1 and KDR were major HPV-up-regulated 223 
genes encoding hub proteins that connected a number of cell growth and apoptosis 224 
signalling pathways. IL-1B and REL, an NFkB family transcriptional co-activator, linked HPV-225 
down-regulated cytokine and VEGF (Figure 5, Supplementary Table S3).  226 
 227 
Verification of gene expression changes due to HPV16 infection  228 
Six genes from among the most statistically highly significant changes (Table 2: padj values 229 
are shown where p=0.05 in the triplicate data set is given the value of 1) were selected for 230 
further study (negative: DSG1, SERPINB3, KRT10, positive: VTCN1, KDR, AZGP1). 231 
Although IL1B had a padj =1 (actual p-value=0.05) it was also included because expression 232 
of this important cytokine was found to be a key gene network hub in both undifferentiated 233 
(17) and differentiated HPV-infected cells (Figure 5). These genes all encode proteins with 234 
known metabolic or immune/inflammatory roles in the normal epithelium. KRT10 is a 235 
differentiation-specific keratinocyte filament protein. DSG1 is a calcium-binding desmosome 236 
regulator. KDR (vascular endothelial growth factor receptor 2, VEGFR-2) has an autocrine 237 
function in cell proliferation, adhesion and migration (36). IL1B “node” cytokine activates 238 
adaptive immunity. VTCN1 is a T-cell activation inhibitor. SERPINB3 controls epithelial 239 
inflammatory responses and AZGP1 is induced by IFNγ in keratinocytes (37). mRNA 240 
expression in NIKS versus NIK16 cells and W12 cells was validated by qRT-PCR (Table 2). 241 
Protein levels encoded by these mRNAs were examined in undifferentiated and 242 
differentiated NIKS, NIKS16 and W12 cells (Figure 6). Levels of AZGP1, KDR, 243 
DSG1,KRT10, and involucrin increased upon NIKS16 and W12 cell differentiation, while 244 
SERPINB3 levels decreased and VTCN1 levels did not change. Compared to differentiated 245 
NIKS cells, there were higher levels of VTCN1, AZGP1 and KDR in NIKS16 cells but KRT10 246 
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and DSG1 levels were much lower in differentiated NIKS16, compare to NIKS cells, as 247 
expected. SERPINB3 levels were greatly reduced following differentiation of NIKS16, but not 248 
NIKS cells. There is no HPV-negative W12 cell equivalent to NIKS cells so it is not possible 249 
to be sure if the changes in protein expression in W12 cells upon differentiation are due to 250 
HPV infection. These data confirm that selected keratinocyte transcriptomic changes due to 251 
HPV16 infection are reflected in protein levels. 252 
 253 
HPV16 infection-regulated mRNA as biomarkers of cervical disease 254 
It could be argued that the NIKS16 model of the HPV16 life cycle may not directly relate to 255 
cervical HPV infection because NIKS16 cells are foreskin, not cervical, keratinocytes, 256 
However, NIKS16 cells appeared to represent a low grade cervical lesion when grown in raft 257 
culture (22) and the organisation of the HPV life cycle at different anatomical sites is quite 258 
similar (38). HPV16-associated gene expression changes in keratinocytes could be related 259 
to the productive life cycle but could equally be associated with cervical disease progression. 260 
Therefore, to test whether any of the HPV-related changes in keratinocyte gene expression 261 
we detected could have potential as HPV-associated cervical disease biomarkers, we 262 
quantified levels of expression of three up- and three-down-regulated genes (two regulators 263 
of the inflammatory response (IL1B, SERPINB3), two proteins involved in cell signalling 264 
(KDR, VTCN1), and two involved in barrier function (KRT10, DSG)) by RT-qPCR in liquid 265 
based cytology (LBC, Pap smear) samples. Apart from choice due to gene function, IL1B 266 
RNA was chosen for analysis because it encoded a hub in the interactome (Figure 5), 267 
VTCN1 and DSG1 were chosen as representative of very highly significantly altered RNAs, 268 
KRT10 was chosen as a differentiation marker, KDR was chosen as an RNA potentially 269 
involved in cancer formation  and SERPINB3 was chosen because it was an early-identified 270 
cervical cancer marker (39). Due to lack of mRNA we were unable to test AZGP1. A control 271 
cDNA from differentiated W12E cervical keratinocytes was included in each qPCR plate as a 272 
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standard and absolute levels of RNA in the LBC samples (normalised against GAPDH) were 273 
calculated using the Pfaffl standard curve method (40, 41). KRT17 was analysed as a known 274 
biomarker of cervical disease progression (42). Figure 6 shows the mean and range of 275 
values for each mRNA in 7 no detectable disease (NDD), 10 low grade cervical lesion 276 
(CIN1) and 10 high grade cervical lesion (CIN3) samples. Although we analysed 10 samples 277 
graded as NDD, once HPV typing status was revealed, 3 of these were HPV-positive. We 278 
decided to exclude these from the analysis in order to compare HPV-negative with HPV-279 
positive clinical samples. KRT10 mRNA levels were very low making analysis of significance 280 
difficult, and there was high variability in levels of IL1B and VTCN1. However, very high 281 
levels of IL1B mRNA were detected in all patient samples, regardless of disease stage. 282 
DSG1 was significantly increased between no detectable disease (NDD) and low grade 283 
disease but significantly decreased between low grade and high grade disease. KDR and 284 
SERPINB3 levels were significantly up-regulated between low grade and high grade 285 
disease, similar to the positive control, KRT17. These data suggest that RNASeq analysis 286 
has potential to uncover novel biomarkers of cervical disease. 287 
  288 
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Discussion 289 
The aim of our work is to examine how human papillomavirus replication is linked to 290 
keratinocyte differentiation. In particular we are interested in how differentiating keratinocytes 291 
respond to HPV infection during the late, productive phase of the viral life cycle. As a model 292 
to compare HPV-negative to HPV-positive keratinocytes, we used NIKS and NIKS16 cells. 293 
NIKS are spontaneously immortalised neonatal foreskin keratinocytes that have no 294 
alterations in differentiation or apoptosis (43). NIKS16 cells were derived directly from NIKS 295 
cells by stable transfection of the HPV16 genome isolated from W12 cells (22). We have 296 
shown  that the NIKS16 cells adequately supported the infectious viral life cycle (as 297 
previously reported (22)) because several key markers of keratinocyte differentiation and 298 
viral life cycle completion: viral genome amplification, viral late mRNA induction and capsid 299 
protein production, were detected. Moreover, because there was repression of VEGF 300 
pathways, reduced expression of HOX and MMP proteins, and no general up-regulation of 301 
EMT markers, these cells are likely not undergoing tumour progression. Because NIKS cells 302 
are foreskin keratinocytes, they will likely have a number of differences in their gene 303 
expression profile compared to cervical keratinocytes. We did not have access to 304 
spontaneously immortalised HPV-negative cervical keratinocytes but we compared changes 305 
in W12 gene expression with NIKS cells.  There was around 40% identity in the up- and 306 
down-regulated genes between NIKS16 and W12 cells. W12 cells are naturally infected, 307 
female, mucosal epithelial cells while NIKS16 cells are male cutaneous epithelial cells and 308 
spontaneously immortalised, and these significant differences likely account for the 309 
remaining 60% of non-overlapping genes. Therefore, NIKS16 is potentially a more robust 310 
model for HPV16-associated penile lesions than cervical lesions and it will be interesting in 311 
future to compare these data sets with similar sets from differentiated uninfected and 312 
infected cervical keratinocytes. 3D raft culture would undoubtedly provide a superior 313 
approach for examining keratinocyte differentiation and HPV infection. However, for analysis 314 
of late events in the viral life cycle in differentiated keratinocytes, this is technically 315 
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challenging, and difficult to reproduce, because RNA isolation from multiple, microdissected, 316 
upper epithelial layer sections would be required for triplicate RNASeq experiments. Our 317 
current dataset should provide an important basis for subsequent analysis of raft culture 318 
models. 319 
 320 
Many transcriptomic studies have analysed cellular changes during HPV-associated tumour 321 
progression or due to overexpression of viral proteins (14, 15, 18, 21, 44-51). Of the 322 
microarray studies investigating changes due to HPV infection, as opposed to 323 
tumourigenesis, one compared expression of HPV31-positive and negative cervical 324 
keratinocytes (14), a second examined HPV33-negative and positive vaginal keratinocytes 325 
(16) while another compared undifferentiated anogenital keratinocytes with or without 326 
episomal HPV16 and 18 genomes (17). All of these studies focused on the effect of HPV on 327 
basal keratinocytes, the site of viral entry, and initial replication. No studies to date have 328 
examined keratinocyte responses to late events in the viral replication cycle. Moreover, the 329 
previous studies used microarray analysis which does not provide the unparalleled depth of 330 
information available from RNASeq. To our knowledge, this is the first report comparing the 331 
transcriptome of uninfected to HPV-infected differentiated keratinocytes using RNASeq. HPV 332 
infection induced massive changes (2862 additional expression changes compared to HPV-333 
negative NIKS cells) in the keratinocyte transcriptome. Desmosomes, adherens, tight and 334 
gap junction classes were all down-regulated in the presence of HPV16, likely due to HPV16 335 
E6/E7 reactivation of the cell cycle and decreased keratinocyte differentiation (52) as has 336 
been reported previously (17). Together with high level down-regulation of SPRRS, altered 337 
arachidonic acid metabolism and changes in mucins (Supplementary Table S3), one can 338 
conclude that HR-HPV infection results in a broad abrogation of epithelial barrier function 339 
and epithelial integrity. Reduced barrier function could result in increased fragility of cells in 340 
the upper epithelial layers to facilitate viral egress.  341 
 342 
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Keratinocytes are key players in the immune response, and they produce a panoply of 343 
molecules involved in host defence against pathogens. In differentiated NIKS16 344 
keratinocytes, HPV infection altered gene expression related to innate immunity, including 345 
reduced expression of TLR7, IL1A, IL1B, NLRP3, IL36B, and IL32G. TLR7, a pattern 346 
recognition receptor for viral nucleic acids, is upregulated upon keratinocyte differentiation 347 
(35) and activates proinflammatory cytokines, and other molecules involved in the adaptive 348 
immune response. There was a 6-fold down-regulation of TLR7 in the presence of HPV16 349 
suggesting that the virus represses pattern recognition during vegetative viral genome 350 
amplification, but by a different mechanism to that used in undifferentiated keratinocytes 351 
where infection suppresses TLR9 (17). There was a corresponding reduction in NFκB-352 
regulated CCL20, known to be regulated by HPV E7 (53), and required to recruit 353 
Langerhans cells. Indeed, NFκB signalling was affected and the NFκB family member, REL, 354 
was a major HPV-regulated control node in the pathway analysis of negatively regulated 355 
genes (Supplementary Figure 1). Surprisingly, we discovered that the epithelial-specific 356 
IFNκ, and IRF1 that controls type 1 IFNs, were up-regulated by HPV16 in differentiated 357 
keratinocytes. Previously, HPV16 E7 or HPV38 E6E7 were shown to inhibit IRF1 expression 358 
(32, 33), while HPV16 E6 was shown to repress IFNk transcription through promoter 359 
methylation (54). However, these studies used overexpression of the viral oncoproteins. The 360 
levels of E6 or E7 proteins may be much lower in differentiated keratinocytes compared to 361 
that in the undifferentiated epithelial cells or cervical cancer cells used in these studies. In 362 
contrast to E6 and E7, E5 can stimulate IRF1 expression in HaCaT cells (55). Changes due 363 
to expression of the entire virus genome may be more complex and quite different to that 364 
seen with expression of individual viral proteins. Up-regulation of IFITs corresponded with 365 
the observed activation of the type 1 interferon response. Only IFIT1 has been shown to 366 
inhibit HPV replication (56, 57) therefore, the roles of other IFITs in inhibiting HPV infection 367 
remain to be determined. APOBEC3B was up-regulated however, we found no changes in 368 
expression of APOBEC3A, a known HPV restriction factor, but its expression may be 369 
differentially regulated only in less differentiated keratinocytes (58).  The observed up-370 
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regulation of CXCR6 and CXCL12 is in agreement with CXCL12 detection in HPV-induced 371 
lesions and its role in the productive HPV life cycle (59). We also detected changes in some 372 
SERPINs (e.g. SERPINB3) that are involved in the inflammatory/immune response (60). We 373 
did not detected changes in STAT1 that has been shown to be controlled by E6 and E7 (61). 374 
It is possible that it undergoes changes of less than the cut-off of >3.5-fold considered here. 375 
However, STAT1 controls IRF1 expression, which was upregulated 4-fold and STAT1 was a 376 
central node connecting gene pathways regulated by HPV16 (Supplementary Figure 1). Of 377 
course, because we used an immortal cell line, immortalisation could account for some of 378 
the changes we observed. It will be important to analyse innate immune regulators in 379 
differentiated primary cervical keratinocytes in future studies.  Our data reveal that HPV 380 
suppression of intrinsic and innate immunity takes place not only in infected basal epithelial 381 
cells (17) but also in keratinocytes harbouring late events in the HPV life cycle, and that a 382 
differentiation stage-specific set of events may be relevant to this life cycle stage. The 383 
stimulation of the IFN response and viral restriction factors in differentiated HPV-infected 384 
cells requires further study. Production of progeny viral genomes and virions may stimulate 385 
the IFN response and lead to apoptosis and this could aid release and dissemination of virus 386 
particles. 387 
 388 
The E5, E6, E7 and E2 proteins of HPV 16 are known to control cellular gene expression. E6 389 
and E7 control keratinocyte cell cycle and apoptosis and abrogate differentiation. Many of 390 
the changes in gene expression we have observed can be attributed to these functions of 391 
the viral oncoproteins. These changes are clearly important for the replicative life cycle of 392 
HPV16 but could also contribute to HPV persistence and development of neoplasia (6). 393 
Similar to data from one overexpression study of HPV16 E6 in human foreskin keratinocytes 394 
(50), the differentiation marker involucrin, vimentin that is expressed upon epithelial stress, 395 
and signal transduction proteins MEST and H19, were up-regulated in our analysis. 396 
However, we detected none of the other changes affecting cell cycle, proliferation, DNA 397 
damage, metabolism or signalling that have previously been reported (50). We discovered 398 
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only 7 genes (Semaphorin 5A (SEMA5A), CXCL1, ENTPOT, Follistatir (FST), Cytochrome 399 
P450 (CYP) 24A1, Pleckstrin homology-like domain A1 (PHLDA1) and ribosomal proteins 400 
S27-like (RPS27L)) out of a total of 99 altered in another study using siRNA depletion of E6 401 
in HPV-positive tumour cells (47). Compared to a study of W12 cells with integrated HPV16 402 
genomes expressing different levels of E6 and E7, we detected E6-regulated loricrin (LOR) 403 
and cytochrome P450 (CYP) 1B1, and E7-regulated FABP4, SERPINA3, SLURP1 out of the 404 
top 20 genes up-regulated by each protein (62). Only one out of 12 master regulators of E6 405 
or E7 function defined by Smith et al (62) was in common with our study. This was 406 
downregulation of PRDM1 (BLIMP-1) which acts as a repressor of IFN-β gene expression. 407 
E5 overexpression in HaCaT keratinocytes yielded 61 mRNAs with significant changes (21) 408 
but only two of these (Keratin 8, MMP16) were in common with our RNASeq data. In a 409 
microarray study of E2 overexpression in U2OS cancer cells where 74 genes were found to 410 
be regulated, only 3 of these (heterotrimeric G-complex protein 11 (GNG11) involved in cell 411 
signalling, histamine N-methyltranferase (HNMT) involved in methylation of histamine and 412 
SERPINA3 which is up-regulated in response to decreased transglutaminase activity) were 413 
altered in our study. Increased viral oncoprotein expression levels in HPV-positive cancer 414 
cells, or in cells overexpressing viral proteins, compared to the model we have used, i.e. 415 
keratinocytes supporting expression of all viral proteins from the intact HPV16 genome 416 
where expression levels are much lower (3), could explain the fact that we did not detect 417 
many of these changes. Moreover, we have only considered expression changes >3.5-fold, 418 
while these other studies considered 2-fold changes. RNASeq analysis of the W12 tumour 419 
progression series (63) would help to delineate infection versus cancer-related changes.  420 
 421 
Liquid based cytology samples (LBCs, Pap smear samples) contain cells scraped from the 422 
top of the cervical epithelium and thus contain HPV-infected differentiated keratinocytes. 423 
Therefore, some of the mRNA changes we have detailed could be biomarkers of cervical 424 
disease. Very high levels of IL1B mRNA were detected in all patient samples, regardless of 425 
disease stage, likely due to inflammation commonly observed in diseased cervix. Statistically 426 
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significant changes in KDR and SERPINB3 expression, like the known biomarker KRT17, 427 
indicate their potential in identifying high grade cervical disease. DSG1 was significantly 428 
increased between no detectable disease (NDD) and low grade disease but significantly 429 
decreased between low grade and high grade disease. This is in contrast to the clear down-430 
regulation of DSG1 expression due to HPV16 infection of NIKS and suggests either that 431 
NIKS16 cells may not represent a low grade HPV16-positive lesion or that the levels of 432 
DSG1 in cervical keratinocytes is very different to that in foreskin keratinocytes.  433 
 434 
In conclusion, we report for the first time RNASeq analysis of changes in the keratinocyte 435 
transcriptome caused by HR-HPV infection. Infection caused massive changes in epithelial 436 
gene expression. These changes showed mainly a profile expected of viral infection, rather 437 
than tumour progression. The large dataset we have developed opens up the possibility of a 438 
deeper understanding of late events in the HPV replication cycle in response to keratinocyte 439 
differentiation. As well as shedding light on late events during the HPV16 life cycle, the 440 
RNASeq data could uncover potential biomarkers of HPV-associated anogenital disease 441 
progression. From our analysis, DSG1, KDR and SERPINB3 expression may have potential 442 
as robust markers that can risk-stratify cervical disease, i.e. identify cervical disease cases 443 
that have a high probability of regression, and this would be of significant clinical value. 444 
However, further longitudinal studies where biomarker status is linked to clinical outcomes 445 
would be required to validate any biomarkers for such an application.   446 
  447 
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Materials and Methods 448 
Clinical sample panel underlying pathology and HPV status  449 
Anonymised, cervical liquid based cytology samples were obtained from the Scottish 450 
National HPV archive which holds Generic Scotland A Research Ethics Committee approval 451 
for Research Tissue banks (REC Ref 11/AL/0174) for provision of samples for HPV related 452 
research after approval from an independent steering committee. The Scottish HPV Archive 453 
also comes under the auspice of the NHS Lothian Bioresource.  The panel comprised HPV 454 
negative/cytology negatives samples (no disease, n=7) samples with low-grade cytological 455 
abnormalities with histological confirmation of cervical intraepithelial neoplasia (CIN) 1 (low-456 
grade disease, n=10) and samples with high-grade cytological abnormalities with histological 457 
confirmation of CIN2 or worse, including cancer (high-grade disease, n=10). Cytology 458 
grades were reported according to the British Society for Clinical Cytopathology (BSCC) 459 
classification (64-66).  HPV testing was performed by the Optiplex HPV genotyping Assay 460 
(Diamex, Heidelberg, Germany) according to manufacturer’s instructions. The Optiplex test 461 
is a PCR based assay which uses a luminex platform for the detection of 24 individual HPV 462 
types including all established as high-risk according to the International Agency on 463 
Research on Cancer. For the purposes of this panel, the main function of the genotyping 464 
was for the annotation of no disease “controls”. Women with negative cytology and HPV 465 
negative status are at a very low risk of underlying disease (negative predictive value for a 466 
high grade lesion of >95% (67)) All experiments were performed in compliance with relevant 467 
laws and institutional guidelines and in accordance with the ethical standards of the 468 
Declaration of Helsinki. 469 
 470 
Cell lines 471 
W12E (24), NIKS (43), and NIKS16 cells (22) were co-cultured in E-medium with mitomycin 472 
C-treated J2 3T3 fibroblast feeder cells as previously described (24).  Differentiation was 473 
induced by growth to high density in 1.2 mM Ca++ (24). 3T3 cells were grown in DMEM with 474 
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10% donor calf serum. Prior to harvesting, 3T3 cells were removed by trypsinisation and 475 
cells layers washed twice with PBS. All cells were maintained under humidified 5% CO2 95% 476 
air at 37°C. 477 
RNA isolation – cell lines 478 
Protocols followed the manufacturer’s instructions. Total RNA was prepared using Qiagen 479 
RNeasy kit.  RNA was quantified by measuring the ratio of absorbance at 260 and 280 nm 480 
using a Nanodrop ND-1000 spectrophotometer (ThermoScientific). Polyadenylated RNA was 481 
prepared using an oligo-dT-based mRNA extraction kit (Oligotex, Qiagen).  482 
RNA isolation – clinical samples 483 
LBC cells in 4ml in PreservCyt collection medium (Cytyc Corporation) were pelleted by 484 
centrifugation in a Beckman GPR bench top centrifuge at 1500g for 10 min.  The cell pellet 485 
washed with sterile PBS. RNA extraction was carried out using the RNeasy miRNA 486 
preparation kit (Qiagen). RNA was quantified and purity assessed by measuring the ratio of 487 
absorbance at 260 and 280 nm using a Nanodrop ND-1000 spectrophotometer.  488 
qRT-PCR 489 
For cell line and clinical samples, DNA was removed using Maxima DNase and treated RNA 490 
was reverse transcribed using Maxima First Strand cDNA synthesis kit according to 491 
manufacturer’s instructions (ThermoScientific). Standard curves were generated as 492 
recommended (Applied Biosystems instruction manual). Triplicate amplification reactions 493 
containing 100 ng cDNA each were carried out.  GAPDH and β-actin were used as the 494 
internal standard controls. Probes and primers are: GAPDH F: 5’-495 
GAAGGTGAAGGTCGGAGT-3’, GAPDH R: 5’- GAAGATGGTGATGGGATTTC-3’, GAPDH 496 
Probe: 5’-CAAGCTTCGTTCTCAGCC. KRT10F: 5’- TGGTTCTTGCCTCAGAAGAGCTGA-497 
3’, KRT10 R: 5’- AGTACACGGTGGTGTCTGTGTCAT-3’, KRT10 Probe: 498 
TGTGTCCACTGGTGATGGGAATGTGG-3’. DSG1 F: 5’- ACGTTCACGATAACCGACCAGC 499 
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AT-3’, DSG1 R: 5’- ATTCCATGCAAATCACGGCCAGAG-3’, DSG1 Probe: 5’- AACGTGGT 500 
AGTGACAGAGAGAGTGGT-3’. KDR F: 5’- TGGTTCTTGCCTCAGAAGAGCTGA-3’, KDR 501 
R: 5’- AGTACACGGTGGTGTCTGTGTCAT-3’, KDR Probe: 5’-502 
TGGCATCTGAAAGCTCAAACC 503 
AGACA-3’. IL1B F: 5’- TCTGTACCTGTCCTGCGTGTTGAA-3’, IL1B R: 5’- TGCTTGAGAGG 504 
TGCTGATGTACCA-3’, IL1B Probe: 5’- CAAGCTGGAATTTGAGTCTGCCCAGT-3’. VTCN1 505 
F: 5’-CACCAGGATAACATCTCTCAGTGAA-3’, VTCN1 R: 5’- TGGCTTGCAGGGTAGAATG 506 
A-3’, VTCN1 Probe: 5’- AAGCTGAAGATAATCCCATCAGGCAT-3’. SERPINB3 F: 5’- 507 
GCTGC 508 
CAAATGAAATCGATGGTCTCC-3’, SERPINB3 R :5’- TTCCCATGGTTCTCAACGTGTCCT-509 
3’, SERPINB3 Probe: 5’-AACTCGGTTCAAAGTGGAAGAGAGCT-3’. KRT17 F:  5’- GATGC 510 
GTGACCAGTATGAGAAG-3’, KRT17 R: 5’- CGGTTCAGTTCCTCTGTCTTG-3’, KRT17 511 
Probe: 5’- ATGGCAGAGAAGAACCGCAAGGAT-3’. Reaction mixes (25 µl) contained 1x 512 
Mastermix (Stratagene), 900 nM primers, 100 nM probe, 300 nM reference dye 513 
(Stratagene).  qPCR reactions were performed and analysed on an Applied Biosystems 514 
7500 Fast System. Graphing and statistical analyses were performed using GraphPad Prism 515 
7. Statistical analysis (all three groups were compared to each other) was performed by 516 
Kruskal-Wallis test and data analysed by one way ANOVA with Tukey’s post-test. A 517 
significance level of p<0.05 was used. 518 
Western blot analysis 519 
Cells were lysed in 2 x protein loading buffer (125 mM Tris (pH 6.8), 4% SDS, 20% glycerol, 520 
10% mercaptoethanol and 0.006% bromophenol blue with fresh protein inhibitor cocktail 521 
(Roche, UK)). Protein extracts were syringe-passaged through a 22-gauge needle 15 times 522 
then sonicated in a Sonibath for three 30 sec pulses to break up DNA strands. The samples 523 
were boiled at 100oC for 5 min before loading on a 12% Novex gel (Invitrogen) and 524 
electrophoresed at 150V for 1 hour in 1X MES buffer. Gels were transferred to a 525 
nitrocellulose membrane using the iBlot transfer kit and iBlot Gel Transfer Stacks (Invitrogen) 526 
 o
n
 O
ctober 25, 2017 by Queen M
ary, University of London
http://jvi.asm.org/
D
ow
nloaded from
 
22 
 
as per the manufacturer’s instructions. Membranes were blocked in 5% milk powder in PBST 527 
at room temperature for at least one hour. Membranes were washed 3 times in PBST for 5 528 
minutes each then incubated with primary antibody. Mouse monoclonal antibodies, GAPDH 529 
(Meridian, 6C5), involucrin (Sigma, I9018), loricirn (Abcam, ab85679), serpinB3 (Sigma, 530 
2F5) and keratin 10 (Abcam, ab9026) were used at a dilution of 1:1000. HPV16 E2 antibody 531 
(Santa Cruz, TVG261) was used at 1:500 dilution. HPV16 L1 antibody (Dako, K1H8) was 532 
used at 1:400 dilution. HPV16 E4 antibody (Gift of J. Doorbar, Cambridge, UK, clone B11) 533 
was used at a dilution of 1:50.  Rabbit polyclonal antibodies DSG1 (Abcam, ab133662), 534 
VEGFR2 (KDR) (Abcam, ab39256). AZGP1 (Invitrogen PA5-44912) were used at 1:1,000 535 
dilution. VTCN1 (Proteintech, 12080-1-AP) was used a a dilution of 1:500. The blots were 536 
incubated in their respective antibody for 1 hour at room temperature or overnight at 4oC. 537 
After 1 hour, the blots were washed 3 times in PBS-T for 5 min. They were then placed in 538 
secondary antibody for 1 hour (HRP-linked goat anti-mouse or goat anti-rabbit (Pierce) were 539 
used at 1:2000 dilution. Blots were washed 3 times in PBST for 5 minutes before being 540 
incubated with ECL western blot substrate. The blots were exposed to X-ray film 541 
(ThermoScientific) and processed in an X-Omat processor. 542 
 543 
Illumina sequencing 544 
Integrity of RNAs was assessed using an Agilent 2100 Bioanalyser. cDNA was synthesised 545 
using reagents from the TruSeq RNA Sample Preparation kit (Illumina) according to the 546 
manufacturer’s instructions. cDNA libraries were sequenced with a 73 base single-end read 547 
on an Illumina Genome Analyser IIx at the Glasgow Polyomics facility at the University of 548 
Glasgow. Samples have been submitted to SRA@ncbi.nih.gov. STUDY: PRJNA379358 549 
(SRP104232). SAMPLE: NIKS16_D11_Mar17 (SRS2131727), EXPERIMENT: Differentiated 550 
NIKS16 cells (SRX2745325) RUN: NIKS_HPV16_D11_Mar17.fq.gz (SRR5457256). 551 
SAMPLE: NIKS16_D5_Mar17 (SRS2131728), EXPERIMENT: Undifferentiated NIKS16 cells 552 
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(SRX2745326), RUN: NIKS_HPV16_D5_Mar17.fq.gz (SRR5457258). SAMPLE: 553 
NIKS_D11_Mar17 (SRS2131729), EXPERIMENT: Differentiated NIKS cells (SRX2745327), 554 
RUN: NIKS_D11_Mar17.fq.gz (SRR5457259). SAMPLE: NIKS_D5_Mar17 (SRS2131730),  555 
EXPERIMENT: Undifferentiated NIKS cells (SRX2745328), RUN: NIKS_D5_Mar17.fq.gz 556 
(SRR5457260) 557 
 558 
Computational analysis 559 
Datasets were cleaned of reads with runs > 12Ns.  Alignment to the human cDNA set 560 
(145,786 cDNAs – downloaded on 28th November 2011) was performed using Bowtie 561 
version 0.12.7.  Further alignment to an updated human cDNA set (180,654 cDNAs 562 
downloaded April 30th 2012) was carried out using BWA 0.7.12-r1039 . DESeq implemented 563 
in BioConductor (68) was used to select cellular genes whose expression was up or down-564 
regulated by HPV in NIKS16 compared to NIKS cells implemented in the R environment. 565 
The raw read counts were normalised using (RPKM). DESeq uses a negative binomial error 566 
distribution to model transcript abundance and determine the differential expression. The 567 
significance of differential expression was estimated for each gene and then corrected for 568 
multiple comparisons (Padj). The top 1000 differentially expressed genes based on log-fold 569 
change (Log2FoldChange) of >1.8 (3.5-fold change) are listed in Supplementary Table S3. 570 
Functional analysis of differentially expressed genes 571 
GO (69) and KEGG (70) enrichment analyses were performed using Cytoscape 572 
(http://cytoscape.org/) with ClueGO (Version 2.3.2) (71). The statistical test used for the 573 
enrichment was based on a two-sided hypergeometric option with a Bonferroni step-down 574 
correction, a P-value less than 0.05 and a kappa score of 0.4.   575 
 576 
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Table 1. Changes in expression of immune regulatory molecules and viral restriction factors. 589 
 590 
  591 
PRR: pattern recognition receptor. IFN, interferon. 592 
  593 
Gene ID Category Negative fold 
change 
Positive fold 
change 
TLR7 PRR 6-fold  
NLRP3 Inflammasome 
component 
7-fold  
IL1A Cytokine 7-fold  
IL1B Cytokine 4-fold  
IL32G Cytokine 17-fold  
IL36B Cytokine 6-fold  
CCL20 Chemokine 7-fold  
CCL28 Chemokine  5-fold 
CXCL12 Chemokine  4-fold 
CX3CL1 Chemokine  32-fold 
APOBEC3C Restriction factor  4-fold 
IFIT1 Restriction factor  6-fold 
IFIT2 Restriction factor  7-fold 
IFIT3 Restriction factor  7-fold 
IFIT5 Restriction factor  4-fold 
CD74 Restriction factor  4-fold 
AOSL Restriction factor  4-fold 
RTP4 Restriction factor  13-fold 
IRF1 IFN regulatory 
transcription factor 
 4-fold 
IFNκ Interferon kappa  8-fold 
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 594 
Table 2. RNASeq expression changes in mRNAs of statistical significance (p<0.025) verified 595 
by qPCR 596 
Gene ID Padj NIKS16/NIKS-
fold change 
RNASeq 
NIKS16/NIKS-
fold change 
qPCR 
W12/NIKS-
fold change 
qPCR 
Gene Function 
DSG1 2.05 
x10
-5 
-19.95 -4.20 -3.52 Desmoglein1: calcium-
binding desmosome 
regulator 
IL1B 1 -8.68 -5.65 -7.73 Interleukin 1b: 
inflammatory response 
regulator 
SERPINB3 0.008 -8.40 -4.28 -4.410 Intracellular protease 
inhibitor, inhibits active 
inflammatory response 
KRT10 0.021 -7.07 -10.26  -3.70 Keratin10: epithelial 
cytofilament 
KDR 0.025 10.21 10.10 4.30 VEGFR-2, tyrosine 
kinase receptor 
VTCN1 1.4 x 
10
-9 
46.12 8.94 10.56 V-set domain-
containing T-cell 
activation inhibitor-1 
AZGP1 2.05 
x10
-5
 
12.64 7.49 8.31 Zinc alpha-2 
glycoprotein: lipid 
metabolism 
GAPDH  1 1 1 Glyceraldehyde-3-
phosphate 
dehydrogenase 
(control) 
Beta-actin  1 1 1 Actin (control) 
 597 
  598 
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Figure Legends 816 
Figure 1. Characterisation of the HPV16 life cycle in NIKS16 and W12 cells. A. 817 
Expression levels of keratinocyte protein differentiation markers and viral L1 protein in 818 
undifferentiated (U = monolayer culture for 5 days) and differentiated (D = monolayer culture 819 
for 13 days) W12 and NIKS16 cells. GAPDH is shown as a loading control. B. Expression 820 
levels of viral E2 and E4 proteins at 8 (mid differentiation phase) and 13 (differentiated) days 821 
of a time course of NIKS16 differentiation in monolayer culture. C. Time course of involucrin 822 
protein expression over a 13 day differentiation period (monolayer cells are mostly 823 
undifferentiated after 5 days culture and fully differentiated after 13 days of culture) for NIKS 824 
and NIKS16 cells. invol, involucrin.  D. Absolute quantification by qPCR of L1 gene copies, 825 
as a measure of viral genomes, in differentiated W12 and NIKS16 cells. E. Viral late mRNA 826 
levels quantified by detecting L1-containing mRNAs by qRT-PCR in undifferentiated and 827 
differentiated W12 and NIKS16 cells.  Invol, involucrin. K10, Keratin 10. 828 
Figure 2. HPV16 infection induces massive changes in the keratinocyte transcriptome. 829 
A. mRNA numbers expressed versus the level of expression of each individual mRNA in 830 
undifferentiated (U) versus differentiated (D) NIKS (HPV-negative) cells. B. mRNA numbers 831 
expressed versus the level of expression of each individual mRNA in undifferentiated (U) 832 
versus differentiated (D) NIKS16 (HPV-positive) cells. C. Venn diagram showing the 833 
percentage identity between upregulated genes of NIKS and NIKS16 cells compared to 834 
NIKS and W12 cells.  D. Venn diagram showing the percentage identity between 835 
downregulated genes of NIKS and NIKS16 cells compared to NIKS and W12 cells. Identity 836 
was determined using the GFOLD tool to calculate the differential fold changes of the two 837 
comparisons. 838 
 839 
Figure 3. Keratinocyte differentiation and epithelial barrier function is altered by HPV 840 
infection. Significant changes in expression (>log2=1.8; 3.5-fold) of proteins involved in 841 
 o
n
 O
ctober 25, 2017 by Queen M
ary, University of London
http://jvi.asm.org/
D
ow
nloaded from
 
36 
 
keratinocyte differentiation and epithelial barrier function comparing HPV16-infected, 842 
differentiated NIKS keratinocytes to uninfected, differentiated NIKS keratinocytes. These are 843 
the mean values from three separate RNASeq experiments A. Markers of differentiation 844 
(filaggrin, loricrin, involucrin and transglutaminase (TGM1)). B. Keratins (K). C. 845 
Desomosomal proteins, desmogleins (DSG) 1 and 4 and desmocoilin (DSC). D. Gap 846 
junction proteins, connexins (Cx) 26, 30.2 and 32.  E. Claudins. F. Cadherins. G. small 847 
proline rich proteins (SPRRs). 848 
 849 
Figure 4. ClueGO analysis of significantly up-and down-regulated genes in HPV16-850 
infected, differentiated NIKS keratinocytes compared to uninfected, differentiated 851 
NIKS keratinocytes. We used CluePedia, which extends ClueGO (71) functionality down to 852 
genes, and visualizes the statistical dependencies (correlation) for markers of interest from 853 
the experimental data. A. Gene ontology (GO) pathway terms specific for up-regulated 854 
genes. B. GO pathway terms specific for down-regulated genes. The bars represent the 855 
numbers of genes associated with the term on the left hand side. The percentage of altered 856 
genes is shown above each bar. Red asterisks refer to significance. C. Functionally grouped 857 
network for up-regulated genes. D. Functionally grouped networks for down-regulated 858 
genes. Only the label of the most significant term per group is shown. The size of the nodes 859 
reflects the degree of enrichment of the terms. The network was automatically laid out using 860 
the organic layout algorithm in Cytoscape. Only functional groups represented by their most 861 
significant term were visualized in the network. Padj< 0.05 changes were analysed. 862 
Figure 5. Interactome of negatively and positively changed genes comparing 863 
differentiated NIKS with differentiated NIKS16 cells.  Interactome of genes linked 864 
through statistical correlation of A. up-regulated and B. down-regulated genes from the 865 
experimental data (p-value <0.05). Grey lettering, and diamonds indicates genes identified in 866 
the RNASeq data set. Black lettering indicates linked genes. Nodes for genes identified 867 
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in the data set are indicated by black box outlines. Dots/lines surrounding nodes indicate the 868 
numbers of linked pathways. The pathways analysis was produced using Cluepedia 869 
(http://apps.cytoscape.org/apps/cluepedia). 870 
 871 
Figure 6. Western blot analysis of proteins levels encoded by selected, significantly 872 
altered mRNAs (Table 2). Protein extracts were prepared from undifferentiated and 873 
differentiated HPV-negative NIKS and HPV16-positive NIKS16 and W12 cell populations. 874 
Much greater levels of involucrin (invol) were detected in the differentiated, compared to the 875 
undifferentiated cell populations indicating differentiation was achieved. GAPDH was used a 876 
protein loading control. A. Protein levels corresponding to significantly up-regulated mRNAs. 877 
B. Protein levels corresponding to significantly down-regulated mRNAs. U, undifferentiated. 878 
D, differentiated. 879 
Figure 7. Expression levels of selected, significantly altered mRNAs in different 880 
grades of HPV-associated pre-neoplastic cervical disease. mRNA expression levels 881 
were calculated from qPCR data using GAPDH and beta-actin as the internal controls and 882 
expressed relative to levels in a single sample of differentiated, HPV16-positive W12 cell 883 
RNA that was included in every PCR run. NDD, no detectable disease/borderline, all HPV-884 
negative. Low grade, cervical intraepithelial neoplasia 1 (CIN1), all HPV-positive. High grade 885 
disease, cervical intraepithelial neoplasia 1 (CIN3), all HPV-positive. 886 
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